Biotech announced that on September 8, 2021, Beijing time, the company signed a licensing and commercialization agreement with SandoZag to license the company's exclusive product commercialization rights in the US, Europe, Canada and most other international markets not covered by BAT1706 cooperation to Sandoz for a fee. The total amount of down payments and milestone payments reached up to $155 million, including a down payment of $27.5 million, cumulative milestone payments of no more than $127.5 million, and a double-digit percentage share of profits. As agreed in the agreement, the company recently received a milestone payment of US$4.50 million from Sandoz.

Biotech announced that on September 8, 2021, Beijing time, the company signed a licensing and commercialization agreement with SandoZag to license the company's exclusive product commercialization rights in the US, Europe, Canada and most other international markets not covered by BAT1706 cooperation to Sandoz for a fee. The total amount of down payments and milestone payments reached up to $155 million, including a down payment of $27.5 million, cumulative milestone payments of no more than $127.5 million, and a double-digit percentage share of profits. As agreed in the agreement, the company recently received a milestone payment of US$4.50 million from Sandoz.